Costs of second allogeneic hematopoietic cell transplantation.

摘要

raft failure, disease recurrence and secondary malignancy are the main indications for a second allogeneic transplant following a prior allogeneic (allo-allo) or autologous (auto-allo) hematopoietic cell transplantation (HCT). Reported outcomes are generally poor, especially for the allo-allo group. The role of planned tandem auto-allo transplants for myeloma and lymphoma is continuing to evolve. Our objective was to describe the cost profile of second HCT and evaluate the relationship between total costs, baseline patient characteristics and post-transplant complications. Clinical information and medical costs of 245 patients (allo-allo: 55, auto-allo: 190) who underwent a second HCT at Fred Hutchinson Cancer Research Center between 2004 and 2010 were collected. Linear regression was used to evaluate the associations between baseline patient characteristics, clinical events and costs for the first 100 days after transplantation. Median costs of the second allogeneic HCT were